Tumor-induced osteomalacia: An overview.

Autor: Jadhav SS; Trustwell Hospital, JC road, Bangalore, Karnataka 560002, India. Electronic address: drswatijadhav1980@gmail.com., Shah R; Harikrushna Hormone Clinic, 304, 3rd Floor, Ashwamegh, Opposite Vyamshala, Anand, Gujarat, India. Electronic address: rk_shreeji@yahoo.com., Patil V; Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India. Electronic address: viru.patil33@gmail.com.
Jazyk: angličtina
Zdroj: Best practice & research. Clinical endocrinology & metabolism [Best Pract Res Clin Endocrinol Metab] 2024 Mar; Vol. 38 (2), pp. 101834. Date of Electronic Publication: 2023 Oct 20.
DOI: 10.1016/j.beem.2023.101834
Abstrakt: Tumor-induced osteomalacia (TIO) is rare paraneoplastic syndrome of hypophosphatemic osteomalacia, caused by phosphaturic factors secreted by small mesenchymal origin tumors with distinct pathological features, called 'phosphaturic mesenchymal tumors'. FGF23 is the most well-characterized of the phosphaturic factors. Tumors are often small and located anywhere in the body from head to toe, which makes the localisation challenging. Functional imaging by somatostatin receptor-based PET imaging is the first line investigation, which should be followed with CT or MRI based anatomical imaging. Once localised, complete surgical excision is the treatment of choice, which brings dramatic resolution of symptoms. Medical management in the form of phosphate and active vitamin D supplements is given as a bridge to surgical management or in inoperable/non-localised patients. This review provides an overview of the epidemiology, pathophysiology, pathology, clinical features, diagnosis, and treatment of TIO, including the recent advances and directions for future research in this field.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: